Birgit M. Schoeberl Net Worth

The estimated Net Worth of Birgit M. Schoeberl is at least $1.75 Million dollars as of 25 July 2016. Birgit Schoeberl owns over 50,000 units of Merrimack Pharmaceuticals Inc stock worth over $1,749,890 and over the last 10 years Birgit sold MACK stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Birgit Schoeberl MACK stock SEC Form 4 insiders trading

Birgit has made over 3 trades of the Merrimack Pharmaceuticals Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Birgit exercised 50,000 units of MACK stock worth $106,000 on 25 July 2016.

The largest trade Birgit's ever made was exercising 62,057 units of Merrimack Pharmaceuticals Inc stock on 9 June 2015 worth over $131,561. On average, Birgit trades about 25,715 units every 83 days since 2015. As of 25 July 2016 Birgit still owns at least 115,657 units of Merrimack Pharmaceuticals Inc stock.

You can see the complete history of Birgit Schoeberl stock trades at the bottom of the page.

What's Birgit Schoeberl's mailing address?

Birgit's mailing address filed with the SEC is C/O MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE, MA, 02139.

Insiders trading at Merrimack Pharmaceuticals Inc

Over the last 13 years, insiders at Merrimack Pharmaceuticals Inc have traded over $1,152,598 worth of Merrimack Pharmaceuticals Inc stock and bought 3,978,994 units worth $28,464,218 . The most active insiders traders include Eric Western Standard Llcwe..., Robert J. Mulroy, and Gary L Crocker. On average, Merrimack Pharmaceuticals Inc executives and independent directors trade stock every 18 days with the average trade being worth of $459,997. The most recent stock trade was executed by Eric Western Standard Llcwe... on 26 December 2023, trading 49,550 units of MACK stock currently worth $651,583.

What does Merrimack Pharmaceuticals Inc do?

merrimack is a fully integrated biopharmaceutical company that views cancer as a complex engineering challenge. through systems biology, which brings together the fields of biology, computing and engineering, merrimack aims to decrease uncertainty in drug development and clinical validation, and move discovery efforts beyond trial and error. such an approach has the potential to make individualized treatment of patients a reality. merrimack's first commercial product, onivydetm (irinotecan liposome injection), was approved by the u.s. fda on october 22, 2015. with four additional candidates in clinical studies, several in preclinical development and multiple biomarkers designed to support patient selection, merrimack is building one of the most robust oncology pipelines in the industry. for more information, please visit merrimack's website at www.merrimack.com or connect on twitter at @merrimackpharma.

Complete history of Birgit Schoeberl stock trades at Merrimack Pharmaceuticals Inc

Merrimack Pharmaceuticals Inc executives and stock owners

Merrimack Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Ulrik Nielsen,
  Independent Director
• Gary Crocker,
  Chairman of the Board, President, Treasurer
• Dr. Ulrik B. Nielsen,
  Co-Founder & Independent Director
• Gary L. Crocker M.B.A., MBA,
  Pres, Treasurer, Principal Financial Officer, Principal Accounting Officer, CEO & Chairman
• Tim Surgenor,
  IR Contact Officer
• Russell Ray,
  Independent Director
• Noah Levy,
  Independent Director
• Eric Andersen,
  Independent Director
• Timothy R. Surgenor,
  Sec.
• Dr. Daryl C. Drummond Ph.D.,
  Head of Research
• Dr. Fazal R. Khan Ph.D.,
  Sr. VP of Manufacturing
• Ellen K. Forest,
  Head of HR
• Geoffrey Grande C.F.A.,
  Sr. Director of Communications
• Dr. Anthony J. Sinskey Ph.D., Sc.D.,
  Co-Founder and Scientific Advisor
• Ana Radeljevic,
  
• Sergio L. Santillana,
  Chief Medical Officer
• John M. Dineen,
  Director
• Yasir B. Al Wakeel,
  CFO and Head of Corp Dev
• Jeffrey A Munsie,
  General Counsel
• James H. Quigley,
  Director
• John Mendelsohn,
  Director
• William A. Sullivan,
  CFO and Treasurer
• Edward J. Stewart,
  SVP & Pres, Healthcare Sol
• Peter N Laivins,
  Head of Development
• Michael E Porter,
  Director
• Richard Peters,
  President and CEO
• Robert J. Mulroy,
  President and CEO
• Birgit M. Schoeberl,
  Head of Discovery
• Vivian S Lee,
  Director
• William M. Mc Clements,
  Head of Corporate Operations
• George Demetri,
  Director
• Thomas E. Jr. Needham,
  Chief Business Officer
• Jean M. Franchi,
  Chief Financial Officer
• Capital Management, Llcjfl ...,
  
• Lp22 Nw Fund, Lp22 Nw Fund ...,
  
• Gordon J. Fehr,
  Director
• Anthony J Sinskey,
  Director
• James Van B. Dresser,
  Director
• Sarah E Nash,
  Director
• Fazal R. Khan,
  SVP of Manufacturing
• Robert C Gay,
  Director
• Walter M Phd Lovenberg,
  Director
• Clet M. Niyikiza,
  EVP of Development
• Jason Aryeh,
  10% owner